Docetaxel: A Review of its Use for the First-Line Treatment of Advanced Castration-Resistant Prostate Cancer

ISSN： 0012-6667

Source： Drugs, Vol.72, Iss.11, 2012-07, pp. : 1559-1577

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Abiraterone Acetate: A Guide to Its Use in Metastatic Castration-Resistant Prostate Cancer

By Scott Lesley J. Yang Lily P.H. Lyseng-Williamson Katherine A.

Drugs & Aging, Vol. 29, Iss. 3, 2012-03 ,pp. : 243-248

Adis International

Access to resources Recommend Favorite

Clinical activity and tolerability of enzalutamide (MDV3100) in patients with metastatic, castration-resistant prostate cancer who progress after docetaxel and abiraterone treatment

By Badrising Sushil van der Noort Vincent van Oort Inge M. van den Berg H. Pieter Los Maartje Hamberg Paul Coenen Jules L. van den Eertwegh Alfons J. M. de Jong Igle J. Kerver Emile D. van Tinteren Harm Bergman Andries M.

Cancer, Vol. 120, Iss. 7, 2014-04 ,pp. : 968-975

Blackwell Publishing

Access to resources Recommend Favorite

Somatostatin analog lanreotide in the treatment of castration-resistant prostate cancer (CRPC)

By Mitsogiannis Iraklis C Skolarikos Andreas Deliveliotis Charalambos

Expert Opinion on Pharmacotherapy, Vol. 10, Iss. 3, 2009-02 ,pp. : 493-501

Informa Healthcare

Access to resources Recommend Favorite

New agents and strategies for the hormonal treatment of castration-resistant prostate cancer

By Sharifi Nima

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 7, 2010-07 ,pp. : 837-846

Informa Healthcare

Access to resources Recommend Favorite

Docetaxel plus oral metronomic cyclophosphamide: A phase II study with pharmacodynamic and pharmacogenetic analyses in castration-resistant prostate cancer patients

Cancer, Vol. 120, Iss. 24, 2014-12 ,pp. : 3923-3931

Blackwell Publishing

Access to resources Recommend Favorite